Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2014

View Archived Issues

Acceleron begins phase I trial of new muscle drug

NIH awards funding to Rare Diseases Clinical Research Network

Boston Strategics enters agreement with Molecular Response

Domainex and Auspherix collaborate to develop antibiotics to treat resistant bacterial infections

ZERO Cancer Research Fund supports prostate cancer early detection work at UCSF

Pentamer Pharmaceuticals seeks crowdfunding to support Ebola virus vaccine development

Heidelberg Pharma extends ADC research collaboration with Roche

Selecta, JDRF and Sanofi to develop a synthetic vaccine particle immunotherapy for type 1 diabetes

New data provided on anti-inflammatory cystic fibrosis candidate CTX-4430

In vivo and in vitro data for novel antisense oligonucleotide for the treatment of CF

Bayer Schering Pharma patents new Wnt signaling inhibitors for cancer

Scientists at Global Blood Therapeutics divulge novel prodrugs for sickle cell disease

Novel IDO inhibitors disclosed by Bristol-Myers Squibb

Sanofi Pasteur and Immune Design collaborate on a herpes simplex virus vaccine

AbbVie Board withdraws recommendation of proposed business combination with Shire

Novel FABP inhibitors synthesized by Roche

Cellular Biomedicine launches preclinical research study for COPD

Phase III safety and immunogenicity results for DTaP-IPV in children 4-6 years of age

Phase III results from ESTEEM 1 and 2 trials evaluating apremilast in patients with psoriasis

University of Utah develops use of peptide mimics as a drug target for Ebola

Allegro initiates phase II study of Luminate for DME

U.S. orphan drug designation for radiotracer OPS-202

Duvelisib misses primary endpoint in phase IIa asthma study

Pharmacyclics and Roche to test ibrutinib and obinutuzumab combination in lymphoma and leukemia

Identification of a novel nuclear-encoded mitochondria susceptibility loci for schizophrenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...